Electrocortical Responses to Emotional Stimuli in Psychotic Disorders: Comparing Schizophrenia Spectrum Disorders and Affective Psychosis

Emotion dysfunction has long been considered a cardinal feature across psychotic disorders, including schizophrenia and affective psychosis. However, few studies have used objective markers of emotional function to compare psychotic disorders to one another, and fewer studies have examined such markers within a longitudinal framework. Here, we examine one objective marker of emotional responsivity, the late positive potential (LPP), which is a centro-parietal event-related potential (ERP) that tracks the dynamic allocation of attention to emotional vs. neutral stimuli. We used the LPP to characterize abnormal emotional responsivity by relating it to negative, depressive, and psychotic symptoms among two clinical groups: individuals diagnosed with affective psychosis and individuals with schizophrenia. We also used a long-term longitudinal framework, examining concurrent associations between LPP amplitude and symptom severity, as well as prospective associations with symptoms 4 years later. Participants were 74 individuals with psychotic illness: 37 with schizophrenia spectrum disorders and 37 with a primary affective disorder (psychotic bipolar disorder, psychotic depression). There were no mean-level differences in LPP amplitude between the schizophrenia spectrum and primary affective psychosis group. In the primary affective psychosis group, reduced LPP amplitude was associated with greater depressive, negative, and psychotic symptom severity, both concurrently and at follow-up; associations between LPP and symptoms were not observed within the schizophrenia spectrum group. This pattern of results suggests that the neural correlates of emotion dysfunction may differ across psychotic disorders. One possibility is that schizophrenia is characterized by a decoupling of symptom severity and emotional processing. Such findings underscore the importance of analyzing transdiagnostic samples to determine common or specific symptom relationships across various patient populations.

Introduction

Emotion dysfunction is present in various forms across psychotic disorders, manifesting as negative (e.g., flattened affect), and depressive symptoms (e.g., anhedonia), and even potentially contributing to psychotic symptoms (e.g., paranoia). However, it is currently unclear whether abnormal emotional processes differ across psychotic disorders, and whether emotional processes show differential relationships to symptoms, potentially yielding clinically distinct phenotypes. For example, it is unclear whether emotional processes show differential relationships to symptoms for individuals diagnosed with a primary affective disorder (e.g., major depressive disorder or bipolar disorder) with psychosis compared to those diagnosed with a schizophrenia spectrum disorders. In order to answer such questions, one recent push in clinical science has been the identification of objective neural markers which demonstrate relationships with symptoms (1, 2). Such markers have the potential to objectively index symptom severity, assist in differential diagnosis, and aid in further understanding the mechanisms that underlie emotional disturbances across psychotic disorders (1–3).

One potential neural marker for emotional dysfunction is the Late Positive Potential (LPP). The LPP is an event-related potential (ERP) component typically evident ~300 ms after stimulus onset and at centro-parietal sites. LPP amplitude is increased following pleasant and unpleasant compared to emotionally neutral stimuli, including pictures, words, and faces (4–9). The LPP is thought to index sustained attention to emotionally-salient stimuli (10, 11), and thus may be particularly relevant to symptoms of psychiatric disorders that relate to emotion dysfunction (9). Indeed, several reports examining the LPP in psychiatric populations have suggested that it is associated with depressive symptoms (12–15). For example, LPP amplitude to threatening and rewarding pictures was shown to be reduced in depressed individuals compared to controls (15). Foti and colleagues reported similar findings of lower LPP amplitude to threatening faces in depressed individuals compared to controls (12). Further, some evidence suggests those at-risk for developing depression demonstrate reduced LPP amplitude to pleasant, unpleasant, and neutral stimuli when compared to lower-risk samples (14, 16). In regards to schizophrenia, LPP amplitude to pleasant, but not unpleasant pictures has been found to be reduced in those with schizophrenia vs. controls (13). However, there is also evidence of normative LPP amplitude to affective pictures among those with schizophrenia (17). Thus, consistent evidence suggests lower LPP compared to controls in those with primary affective disorders while evidence for lower LPP in schizophrenia spectrum disorders is less consistent.

While previous reports have been informative in establishing LPP-to-symptom associations within particular diagnostic categories, few studies have examined the LPP across psychotic disorders. In one exception, Horan and colleagues measured LPP during a motivational gradient task where cues signaling potential monetary gain or loss appeared to loom progressively closer to the observer (18). They found differences in temporal dynamics of the LLP between individuals with bipolar disorder and those with schizophrenia. Specifically, the bipolar group was characterized by an early escalation of LPP during cue presentation, whereas the schizophrenia group showed diminished escalation of LPP to either cue (18). While this study was informative in further understanding differences in the temporal dynamics of motivational experience across psychotic disorders, additional samples including a wider variety of psychotic disorders could be useful in better understanding how emotional processes might differ across affective psychosis and schizophrenia spectrum disorders. In addition, the majority of studies assessing LPP in psychiatric populations have been cross-sectional. Such studies are limited in their ability to determine whether abnormalities in LPP are shaped by current symptoms, or if such deficits are more enduring or trait-like. Thus, longitudinal designs are needed to better characterize the nature of LPP deficits and how they may differ across various psychotic disorders (19).

In the current study, we examined relationships between LPP and symptoms of emotional dysfunction within a clinically heterogeneous sample of individuals with psychotic illness. To test the potential transdiagnostic nature of LPP-to-symptom relationships, we contrasted two groups: individuals with schizophrenia spectrum disorders and individuals with a primary affective disorder with psychosis (i.e., psychotic bipolar disorder, psychotic depression). We also utilized a longitudinal approach, examining the relationships between LPP amplitude and concurrent symptom severity as well as symptom severity at a 4-year follow-up. Using these data, we tested two competing hypotheses: (1) Across psychotic disorders, the LPP would demonstrate both cross-sectional and lagged associations of similar magnitude with depressive, negative, and psychotic symptoms, consistent with transdiagnostic, temporally stable (i.e., trait-like) association; (2) LPP amplitude may differ between schizophrenia and affective psychosis (i.e., lower LPP amplitude in affective psychosis) and LPP-to-symptom relationships exhibit diagnostic specificity with more robust associations in those with a primary affective disorder with psychosis than with a schizophrenia spectrum disorder. This second hypothesis is consistent with strong evidence of diminished LPP in those with major depressive disorder (12, 15), but inconsistent with previous work in schizophrenia (20).

Methods

Participants

Participants were recruited from the Suffolk County Mental Health Project (21, 22), an epidemiologic longitudinal study of first admission psychosis. The sampling frame consisted of consecutive first admissions with psychosis to the 12 psychiatric inpatient facilities in Suffolk County, N.Y., from 1989 to 1995. We specifically included individuals within the sample that met diagnostic criteria for schizophrenia, schizoaffective disorder, bipolar disorder with psychosis, or major depressive disorder with psychosis, at a study session 15 years after first admission. The current manuscript is one of multiple published with data collected from this cohort (23–27). Inclusion criteria were: (1) presence of psychosis; (2) IQ > 70; (3) age between 15 and 60 years at admission; (4) resident of Suffolk County; (5) ability to provide informed consent. This study was approved by the Institutional Review Board at Stony Brook University. EEG was collected ~15 years after first admission from 74 participants: 37 participants with 10-year follow-up consensus diagnoses of schizophrenia spectrum disorders (SZ: 23 schizophrenia, 14 schizoaffective disorder) and 37 participants with affective psychosis (AP: 27 bipolar disorder, 10 major depressive disorder). Across our sample of 74 individuals, we had ~95% power to detect an effect size of f ² = 0.15 in a model with three independent variables. Similar effect sizes were found between depression symptom severity and LPP to threatening compared to neutral faces across a sample of individuals with major depressive disorder and healthy controls (12).

Although schizoaffective disorder is characterized by prominent affective disturbances, we included these individuals within the schizophrenia spectrum disorders group instead of the primary affective psychosis group. Previous work has suggested that schizoaffective disorder is better characterized as part of the schizophrenia spectrum than of primary mood pathology (28).

Clinical Assessment

Clinical assessments were conducted concurrently with EEG acquisition (i.e., 15 years after first admission) and at 19-year follow-up. At each assessment, participants were evaluated by master's level interviewers using the Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-IV) (29), the Scale for the Assessment of Positive Symptoms (SAPS) (30), and the Scale for the Assessment of Negative Symptoms (SANS) (31). For the SAPS and SANS, four subscales were identified: reality distortion and disorganization, avolition, and inexpressivity (32). Current depressive symptom severity was operationalized by summing scores for the nine criterion A items for current major depressive disorder on the SCID-IV administered without skip-outs. Items were scored on a 1–3 scale, and the SCID Depression score range from 9 to 27 (33). Finally, a measure of general cognitive ability, reading subtest of the Wide Range Achievement Test-3rd Edition (WRAT-3) (34), was collected at the 19-year time point.

Stimulus Materials and Task

Participants passively viewed 130 images selected from the NimStim set (35)¹. Twenty-six images were presented for each of five facial expressions: happy, sad, angry, afraid, and neutral. These images depicted 26 different actors (13 male, 13 female), such that each actor appeared for each of the five emotional face categories². Each face was presented once, in a pseudorandom order for each participant. Images were presented for 1,000 ms, followed by an inter-trial interval that varied randomly from 1,000 to 1,500 ms. Participants were instructed to simply view the images.

EEG Recording, Processing, and Data Reduction

EEG was recorded using the Active Two BioSemi System, sampled at 1,024 Hz using 34 scalp electrodes and two mastoid electrodes. The electro-oculogram was recorded from four facial electrodes. Offline analysis was performed using Brain Vision Analyzer software (Brain Products). Data were re-referenced to the mastoid average and band-pass filtered from 0.1 to 30 Hz. The EEG was segmented on each trial in a window of −200 to 1,000 ms surrounding image onset, and correction for blinks and eye movements was performed using a regression method (36). Artifact rejection was performed using a semi-automated procedure. Artifacts were defined as a voltage step of more than 50 μV, a difference of 300 μV within a trial, or a maximum difference of <0.5 μV within a 100-ms window; additional artifacts were identified manually. Segments were averaged separately for each image category and baseline corrected relative to the 200-ms pre-stimulus interval. The LPP was scored as the average activity from 400 to 1,000 ms at electrode site Pz (where the response was maximal), similar to previous reports (37–39). A difference score was calculated by subtracting neutral LPP from each emotional stimulus category (i.e., happy, sad, afraid, angry), and these difference scores were used in all analyses. Finally, the Average LPP was created by averaging LPP difference scores across all four emotion categories.

Data Analysis

Relationships between symptom severity (SAPS Reality Distortion, SAPS Disorganization, SANS Avolition, SANS Inexpressivity, and SCID depression) at each assessment point (concurrent and follow-up) and LPP difference scores were examined across the entire sample using separate regression models. Specifically, individual LPP difference scores were entered as the dependent variable and symptoms, group (coded: 0.5 for schizophrenia and −0.5 for affective psychosis), and their interaction were entered as independent variables. Altogether, the main analysis consisted of ten separate regressions, each including either a cross-sectional or follow-up symptom variable. Regression models aimed to quantify the association between LPP and symptom variables and not the prediction of LPP by symptoms, per se. A false discovery rate (FDR) correction was implemented to control for multiple comparisons within symptom clusters (40). Specifically, four FDR clusters were used (1) Cross-sectional mood including SANS Inexpressivity, SANS Avolition, and SCID Depression; (2) Cross sectional psychosis: SAPS Reality Distortion and SAPS Disorganization; (3) Follow-up mood: SANS Inexpressivity, SANS Avolition, and SCID Depression; (4) Follow-up psychosis: SAPS Reality Distortion and SAPS Disorganization.

Results

Demographics

The affective psychosis and schizophrenia spectrum groups were similar in regards to demographic variables (Table 1). Relative to the affective psychosis group, individuals in the schizophrenia spectrum group were more likely to be prescribed antipsychotic medications and showed more severe positive and negative symptoms, although not more severe depression. Significantly more variance was found in cross-sectional and lagged negative and positive symptoms but not depressive symptoms (see Supplemental materials for measures of variance; Table S9).

TABLE 1

Table 1. Demographics.

Group Differences

Grand average ERP waveforms are presented in Figure 1. No group differences were observed between affective psychosis and schizophrenia spectrum groups in LPP difference scores (Table 2). Antipsychotic medication also did not have a significant relationship to LPP (Table S1). In light of the similar mean-level LPP amplitude across groups, subsequent analyses focused on the Average LPP variable as a broader index of emotional reactivity (see the Supplemental Materials Table S2 for analyses conducted within emotion category).

FIGURE 1

Figure 1. (Left) LPP Grand Average Waveform, (Right) Scalp Map illustrating LPP activation.

TABLE 2

Table 2. Group differences in LPP amplitude.

Cross-Sectional Associations With Symptoms

Table 3A describes the main effects of symptoms, group, and their interaction for each regression model (see Figure 2 for scatterplots; see Figure S1 for scatterplots illustrating relationship for SZ and SZA separately). Across these regression models, significant group effects were not observed. A significant symptom effect for psychotic symptoms (SAPS Reality Distortion) was observed such that greater symptom severity was associated with lower LPP amplitude, but all other symptom effects were non-significant. Broadly, associations between LPP difference score amplitude and symptom severity were more robust in the affective psychosis group compared to the schizophrenia group. Specifically, significant interactions between symptom variables and diagnostic group (coded: 0.5 for schizophrenia and −0.5 for affective psychosis) were observed for depressive (SCID Depression), negative (SANS Avolition), and psychotic (SAPS reality distortion) symptoms suggesting more robust negative associations between LPP and symptoms in the affective psychosis compared to the schizophrenia group. All significant interactions maintained significance when controlling for multiple comparisons (see Table S3 of Supplemental Materials for FDR-corrected q-values). The interaction between expressive negative symptoms (SANS Inexpressivity) and group was trend-level, and the interaction between disorganized symptoms (SAPS disorganization) and LPP was not significant (Table 3A). Regression models met the assumptions of normality of the residuals (See Tables S4, S5 of Supplemental Materials for skewness, kurtosis, and Shaprio-Wilk tests of the residuals for each model).

TABLE 3A

Table 3a. Multiple Regressions illustrating the cross-sectional association between Average LPP Difference Scores and symptoms, Group, and the interaction of group and symptoms.

FIGURE 2

Figure 2. Scatterplots illustrating relationships between symptom severity and LPP difference scores averaged across emotion categories.

Symptoms at 4-Year Follow-Up

Table 3B describes the main effects of symptoms (measured 4 years following ERP acquisition), group, and their interaction for each regression model (see Figure 2 for scatterplots; see Figure S1 for scatterplots illustrating relationship for SZ and SZA separately). Across these regression models, no significant effects of group were observed. A significant symptom effect for psychotic symptoms (SAPS Reality Distortion) and a trend-level effect for SANS Avolition were observed such that greater symptom severity was associated with lower LPP amplitude. All other symptom effects were non-significant. Significant interactions between symptom variables and diagnostic group (coded: 0.5 for schizophrenia and −0.5 for affective psychosis) were observed for negative (SANS Avolition) and psychotic (SAPS reality distortion) symptoms suggesting more robust negative lagged associations between LPP and symptoms in the affective psychosis compared to the schizophrenia group. Associations between LPP Amplitude and depressive, disorganized, or inexpressive negative symptoms did not maintain significance at follow-up. When controlling for multiple comparisons, only the interaction between psychotic symptoms and group maintained significance (see Table S3 of the Supplemental Materials for FDR-corrected q-values). Regression models met the assumptions of normality of the residuals (See Tables S4, S5 of Supplemental Materials for skewness, kurtosis, and Shaprio-Wilk tests of the residuals for each model).

TABLE 3B

Table 3b. Multiple regressions describing the lagged associations between Average LPP Difference Scores and Symptoms, Group, and the interaction of group and symptoms.

Further Analysis of LPP Difference Scores

In order to aid in the interpretation of LPP difference scores, we conducted supplementary analyses to determine whether neural response to emotional category or neutral category was driving the observed relationships between LPP difference scores and symptoms (Tables S6a,b of Supplemental Materials). Specifically, we conducted multiple regressions where either LPP to averaged emotion faces or to neutral faces was the dependent variable and symptoms, group, and their interaction were the independent variable. For positive and depressive symptoms, significant interactions between symptoms and group were largely driven by increased LPP amplitude to neutral stimuli. For negative symptoms, significant interactions between symptoms and group were driven by both increased LPP amplitude to neutral stimuli and decreased LPP amplitude to emotional stimuli (Table S6).

Role of Antipsychotic Medications

In order to better understand the role of antipsychotic dose in the aforementioned effects, we conducted similar multiple regressions to those described above but entered chlorpromazine (CPZ) equivalent dose as an additional independent variable [calculated using (41) documenting a score of zero for individuals not currently prescribed antipsychotics]. Critically, CPZ dose was not significantly associated with LPP in any of these models (see Tables S7, S8 of Supplemental Materials). Further, all aforementioned significant symptom by group interactions remained significant when including CPZ into the statistical model (see Tables S7, S8 of Supplemental Materials).

Discussion

The goal of the current study was to test the hypothesis of transdiagnostic relationships between LPP amplitude and symptoms of emotional dysfunction, across putatively distinct psychotic illnesses. We found that significantly greater associations between LPP amplitude and symptom severity in individuals with affective psychosis compared to schizophrenia spectrum disorders for negative, depressive, and psychotic symptoms, thereby suggesting diagnostic specificity for these LPP-symptom relationships. Further, LPP amplitude showed some evidence of specificity to specific symptoms as no significant associations were observed between LPP amplitude and symptoms of disorganization.

Associations between reduced LPP amplitude and symptom severity in the affective psychosis group are consistent with several previous reports in non-psychotic depressed samples (12, 15) or in those at risk for developing depression (14, 16, 42). The current report extends prior findings by demonstrating LPP-to-symptom associations in those with psychotic disorders with a primary affective component suggesting that previous findings may generalize to both psychotic and non-psychotic forms of the illness, and further shows that these relationships for some symptom variables (i.e., avolition) persist over years. However, the current report also suggests that the LPP may be indexing more state-like compared to trait-like variability for depressive symptoms. Future studies of the LPP in major depressive disorder may benefit from more directly examining individuals with and without psychosis in the same sample, and further may benefit isolating avolition as a particularly relevant symptom dimension separate from global depression severity.

While LPP in individuals with affective psychosis was related to symptom severity measures, LPP was not related to any symptom measures in the schizophrenia group. This is consistent with previous studies who find similar LPP amplitude between healthy controls and those with schizophrenia, as well as studies that fail to find significant relationships between symptom severity and LPP in schizophrenia (13, 17). This raises interesting questions as to why LPP amplitude in those with schizophrenia appears insensitive to variations in clinical symptom measures. One possible explanation may be that the psychological and neural mechanisms that give rise to affective disturbance in schizophrenia may differ from affective psychosis. For example, in the moment emotional response may be intact in schizophrenia but decoupled from the retrospective reports of emotional experience measured via clinical interview, potentially due to difficulties encoding and retrieving affective experience (43, 44). In contrast, retrospective reports of emotional experience measured via clinical interview may be better coupled with in-the-moment emotional response in affective psychosis, potentially due to more intact cognitive ability in these individuals when compared to those with schizophrenia (45, 46).

Supplementary analyses revealed that associations between LPP and psychotic and depressive symptoms were largely driven by a larger LPP to neutral stimuli, a pattern that was also evident in the SZ group. In contrast, associations between LPP difference scores and negative symptoms were characterized by blunting of the discrimination between neutral and emotional faces. The associations between psychotic symptoms and neutral LPP in the current report are largely consistent with previous literature, including neuroimaging studies, which report enhanced activation of the limbic system to neutral faces in those at-risk for developing psychosis (47). Kapur and others have proposed that psychosis is associated with aberrant attributions of motivational salience to neutral stimuli (48). The current associations between neutral LPP and psychotic symptoms are consistent with this account. Further, there is some evidence that blunted amygdala responsivity to emotional faces in individuals with major depressive disorder is driven by increased reactivity to neutral faces and that this increased reactivity normalizes with treatment (49). The current results showing that LPP to neutral faces correlates with depressive symptoms are consistent with this account.”

Limitations

The absence of a healthy comparison group limited our ability to interpret group differences between psychiatric groups and healthy controls. However, the aim of the current manuscript was to examine associations between the LPP and symptoms concurrently and years later across psychotic disorders. Further, previous studies have the LPP largely intact in schizophrenia making a healthy control group potentially less informative. Thus, a healthy comparison group was not integral to the examination of the aims of the current study. Second, although we found robust associations between symptoms, in our affective psychosis group, and LPP amplitude, we did not have the statistical power to examine such relationships within individual diagnoses (i.e., major depressive disorder, bipolar disorder). It may be the case that such relationships demonstrate important diagnostic group differences within affective psychosis and this remains an important question for future work. Further, may be important to separately analyze those with schizoaffective disorder. Finally, many of our participants were taking medications that have known influences on emotional processes, and the number of individuals prescribed such medications differed between groups. While medication status did not significantly modulate the relationship between symptoms and LPP amplitude, it remains possible that absence of effects in schizophrenia group may be due to the history of exposure to antipsychotics rather than being characteristic of the illness itself.

Summary

We found modest evidence for negative associations between depressive and psychotic symptom severity and LPP amplitude. However, individuals with primary affective psychosis largely drove these correlations. Specifically, we found robust concurrent and lagged correlations of LPP with symptoms of psychotic, depressive, and negative symptoms not among individuals with schizophrenia but instead among individuals with a primary affective disorder with psychosis, providing some evidence for diagnostic specificity in the neural correlates of emotion dysfunction. These data are consistent with previous findings of robust correlations between depressive symptoms and reduced LPP amplitude in major depression (12), and also consistent with previous reports showing an absence of symptom-to-LPP relationships in those with schizophrenia (13, 17). Our results point to the possibility that similarly assessed symptom domains may arise from different psychological and neural mechanisms across psychotic disorders, underscoring the importance in studying multiple disorders together to further understand psychosis.

Author Contributions

RK implemented the data collection. AC wrote the initial version of the manuscript and conducted initial analyses. All authors provided comments on analyses and approved a final version of the manuscript.

Funding

This work was supported by the National Institutes of Health (MH094398 to RK), Stony Brook University (Clinical Research Scholar Award to RK).

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2018.00586/full#supplementary-material

Footnotes

1. ^Development of the MacBrain Face Stimulus Set was overseen by Nim Tottenham and supported by the John D. and Catherine T. MacArthur Foundation Research Network on Early Experience and Brain Development. Please contact Nim Tottenham at tott0006@tc.umn.edu for more information concerning the stimulus set.

2. ^The NimStim actors used were: 1, 2, 3, 5, 7, 8, 9, 10, 11, 12, 14, 17, 18, 20, 22, 23, 24, 25, 26, 27, 30, 34, 37, 38, 39, and 40.

References

1. Tamminga CA, Pearlson G, Keshavan M, Sweeney J, Clementz B, Thaker G. Bipolar and schizophrenia network for intermediate phenotypes: outcomes across the psychosis continuum. Schizophr Bull. (2014) 40:S131–7. doi: 10.1093/schbul/sbt179

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Hager BM, Keshavan MS. Neuroimaging biomarkers for psychosis. Curr Behav Neurosci Rep. (2015) 2:102–11. doi: 10.1007/s40473-015-0035-4

CrossRef Full Text | Google Scholar

3. Cuthbert BN, Insel TR. Toward new approaches to psychotic disorders: the NIMH research domain criteria project. Schizophr Bull. (2010) 36:1061–2. doi: 10.1093/schbul/sbq108

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Cuthbert BN, Schupp HT, Bradley MM, Birbaumer N, Lang PJ. Brain potentials in affective picture processing: covariation with autonomic arousal and affective report. Biol Psychol. (2000) 52:95–111. doi: 10.1016/S0301-0511(99)00044-7

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Schupp HT, Cuthbert BN, Bradley MM, Cacioppo JT, Ito T, Lang PJ. Affective picture processing: the late positive potential is modulated by motivational relevance. Psychophysiology (2000) 37:257–61. doi: 10.1111/1469-8986.3720257

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Schupp HT, Junghöfer M, Weike AI, Hamm AO. Attention and emotion: an ERP analysis of facilitated emotional stimulus processing. Neuroreport (2003) 14:1107–10. doi: 10.1097/00001756-200306110-00002

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Dillon DG, Cooper JJ, Grent T, Woldorff MG, LaBar KS. Dissociation of event-related potentials indexing arousal and semantic cohesion during emotional word encoding. Brain Cogn. (2006) 62:43–57. doi: 10.1016/j.bandc.2006.03.008

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Foti D, Hajcak G. Deconstructing reappraisal: descriptions preceding arousing pictures modulate the subsequent neural response. J Cogn. Neurosci. (2008) 20:977–88. doi: 10.1162/jocn.2008.20066

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Hajcak G, MacNamara A, Olvet DM. Event-related potentials, emotion, and emotion regulation: an integrative review. Dev Neuropsychol. (2010) 35:129–55. doi: 10.1080/87565640903526504

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Bradley MM. Natural selective attention: orienting and emotion. Psychophysiology (2009) 46:1–11. doi: 10.1111/j.1469-8986.2008.00702.x

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Hajcak G, Dunning JP, Foti D. Motivated and controlled attention to emotion: time-course of the late positive potential. Clin Neurophysiol. (2009) 120:505–10. doi: 10.1016/j.clinph.2008.11.028

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Foti D, Olvet DM, Klein DN, Hajcak G. Reduced electrocortical response to threatening faces in major depressive disorder. Depress Anxiety (2010) 27:813–20. doi: 10.1002/da.20712

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Horan WP, Wynn JK, Kring AM, Simons RF, Green MF. Electrophysiological correlates of emotional responding in schizophrenia. J Abnorm Psychol. (2010) 119:18–30. doi: 10.1037/a0017510

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Nelson BD, Perlman G, Hajcak G, Klein DN, Kotov R. Familial risk for distress and fear disorders and emotional reactivity in adolescence: an event-related potential investigation. Psychol Med. (2015) 45:2545–56. doi: 10.1017/S0033291715000471

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Weinberg A, Perlman G, Kotov R, Hajcak G. Depression and reduced neural response to emotional images: distinction from anxiety, and importance of symptom dimensions and age of onset. J Abnorm Psychol. (2016) 125:26–39. doi: 10.1037/abn0000118

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Kujawa A, Hajcak G, Torpey D, Kim J, Klein DN. Electrocortical reactivity to emotional faces in young children and associations with maternal and paternal depression. J Child Psychol Psychiatry (2012) 53:207–15. doi: 10.1111/j.1469-7610.2011.02461.x

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Horan WP, Foti D, Hajcak G, Wynn JK, Green MF. Intact motivated attention in schizophrenia: evidence from event-related potentials. Schizophr Res. (2012) 135:95–9. doi: 10.1016/j.schres.2011.11.005

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Horan WP, Wynn JK, Hajcak G, Altshuler L, Green MF. Distinct patterns of dysfunctional appetitive and aversive motivation in bipolar disorder versus schizophrenia: an event-related potential study. J Abnorm Psychol. (2016) 125:576–87. doi: 10.1037/abn0000142

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Luck SJ, Mathalon DH, O'Donnell BF, Hämäläinen MS, Spencer KM, Javitt DC, et al. A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. Biol Psychiatry (2011) 70:28–34. doi: 10.1016/j.biopsych.2010.09.021

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Horan WP, Foti D, Hajcak G, Wynn JK, Green MF. Impaired neural response to internal but not external feedback in schizophrenia. Psychol Med. (2012a) 42:1637–47. doi: 10.1017/S0033291711002819

CrossRef Full Text | Google Scholar

21. Bromet EJ, Kotov R, Fochtmann LJ, Carlson GA, Tanenberg-Karant M, Ruggero C, et al. Diagnostic shifts during the decade following first admission for psychosis. Am J Psychiatry (2011) 168:1186–94. doi: 10.1176/appi.ajp.2011.11010048

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Kotov R, Fochtmann L, Li K, Tanenberg-Karant M, Constantino EA, Rubinstein J, et al. Declining clinical course of psychotic disorders over the two decades following first hospitalization: evidence from the Suffolk County Mental Health Project. Am J Psychiatry (2017) 174:1064–74. doi: 10.1176/appi.ajp.2017.16101191

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Foti D, Kotov R, Bromet E, Hajcak G. Beyond the broken error-related negativity: functional and diagnostic correlates of error processing in psychosis. Biol Psychiatry (2012) 71:864–72. doi: 10.1016/j.biopsych.2012.01.007

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Foti D, Kotov R, Hajcak G. Psychometric considerations in using error-related brain activity as a biomarker in psychotic disorders. J Abnorm Psychol. (2013) 122:520–31. doi: 10.1037/a0032618

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Jackson F, Foti D, Kotov R, Perlman G, Mathalon DH, Proudfit GH. An incongruent reality: the N400 in relation to psychosis and recovery. Schizophr Res. (2014) 160:208–15. doi: 10.1016/j.schres.2014.09.039

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Perlman G, Foti D, Jackson F, Kotov R, Constantino E, Hajcak G. Clinical significance of auditory target P300 subcomponents in psychosis: differential diagnosis, symptom profiles, and course. Schizophr Res. (2015) 165:145–51. doi: 10.1016/j.schres.2015.04.013

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Foti D, Perlman G, Hajcak G, Mohanty A, Jackson F, Kotov R. Impaired error processing in late-phase psychosis: four-year stability and relationships with negative symptoms. Schizophr Res. (2016) 176:520–6. doi: 10.1016/j.schres.2016.05.009

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Kotov R, Leong SH, Mojtabai R, Erlanger ACE, Fochtmann LJ, Constantino E, et al. Boundaries of schizoaffective disorder: revisiting Kraepelin. JAMA Psychiatry (2013) 70:1276–86. doi: 10.1001/jamapsychiatry.2013.2350

PubMed Abstract | CrossRef Full Text | Google Scholar

29. First MB, Spitzer RL, Gibbon MWJB, Williams JB. Structured Clinical Interview for DSM-IV axis I disorders. New York, NY: New York State Psychiatric Institute (1995).

30. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa, Iowa City (1984).

31. Andreasen NC. Scale for the assessment of negative symptoms (SANS). Br J Psychiatry (1989) 155:49–52. doi: 10.1192/S0007125000291496

CrossRef Full Text | Google Scholar

32. Kotov R, Foti D, Li K, Bromet EJ, Hajcak G, Ruggero CJ. Validating dimensions of psychosis symptomatology: neural correlates and 20-year outcomes. J Abnorm Psychol. (2016) 125:1103–19. doi: 10.1037/abn0000188

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry (2010) 167:987–93. doi: 10.1176/appi.ajp.2010.09020189

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Wilkinson G. Wide Range Achievement Test-Revision 3. Wilmington, DE: Jastak Association (2001).

35. Tottenham N, Tanaka JW, Leon AC, McCarry T, Nurse M, Hare TA, et al. The NimStim set of facial expressions: judgments from untrained research participants. Psychiatry Res. (2009) 168:242–9. doi: 10.1016/j.psychres.2008.05.006

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Gratton G, Coles MG, Donchin E. A new method for off-line removal of ocular artifact. Electroencephalogr Clin Neurophysiol. (1983) 55:468–84. doi: 10.1016/0013-4694(83)90135-9

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Smith NK, Larsen JT, Chartrand TL, Cacioppo JT, Katafiasz HA, Moran KE. Being bad isn't always good: affective context moderates the attention bias toward negative information. J Person Soc Psychol. (2006) 90:210–20. doi: 10.1037/0022-3514.90.2.210

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Leutgeb V, Schäfer A, Schienle A. An event-related potential study on exposure therapy for patients suffering from spider phobia. Biol Psychol. (2009) 82:293–300. doi: 10.1016/j.biopsycho.2009.09.003

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Moser JS, Krompinger JW, Dietz J, Simons RF. Electrophysiological correlates of decreasing and increasing emotional responses to unpleasant pictures. Psychophysiology (2009) 46:17–27. doi: 10.1111/j.1469-8986.2008.00721.x

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Seri B. (1995) 57:289–300.

Google Scholar

41. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho B-C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry (2010) 67:255–62. doi: 10.1016/j.biopsych.2009.08.040

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Weinberg A, Liu H, Hajcak G, Shankman SA. Blunted neural response to rewards as a vulnerability factor for depression: results from a family study. J Abnorm Psychol. (2015) 124:878–89. doi: 10.1037/abn0000081

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Barch DM, Dowd EC. Goal representations and motivational drive in schizophrenia: the role of prefrontal–striatal interactions. Schizophr Bull. (2010) 36:919–34. doi: 10.1093/schbul/sbq068

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Strauss GP, Gold JM. A new perspective on anhedonia in schizophrenia. Am J Psychiatry (2012) 169:364–73. doi: 10.1176/appi.ajp.2011.11030447

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Barch DM, Sheline YI, Csernansky JG, Snyder AZ. Working memory and prefrontal cortex dysfunction: specificity to schizophrenia compared with major depression. Biol Psychiatry (2003) 53:376–84. doi: 10.1016/S0006-3223(02)01674-8

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Reichenberg A, Harvey PD, Bowie CR, Mojtabai R, Rabinowitz J, Heaton RK, et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull. (2008) 35:1022–9. doi: 10.1093/schbul/sbn044

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Seiferth NY, Pauly K, Habel U, Kellermann T, Shah NJ, Ruhrmann S, et al. Increased neural response related to neutral faces in individuals at risk for psychosis. Neuroimage (2008) 40:289–97. doi: 10.1016/j.neuroimage.2007.11.020

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry (2003) 160:13–23. doi: 10.1176/appi.ajp.160.1.13

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Ritchey M, Dolcos F, Eddington KM, Strauman TJ, Cabeza R. Neural correlates of emotional processing in depression: changes with cognitive behavioral therapy and predictors of treatment response. J Psychiatr Res. (2011) 45:577–87. doi: 10.1016/j.jpsychires.2010.09.007

PubMed Abstract | CrossRef Full Text | Google Scholar